Categories | Inventors

A biomarker for Alzheimer's disease.


OHSU # 1525


Biomarker for Alzheimer’s Disease

Technology Summary:

An easily isolated and measurable biomarker of Alzheimer’s disease (AD), the chemokine receptor6, CCR6, has been identified in peripheral blood monocytes (PBMC’s). Currently, a definite diagnosis of AD requires brain tissue examination at autopsy. Now, an accessible biological sample of blood can be used to identify living patients with Alzheimer’s disease or measure the response to treatment. Levels of CCR6 mRNA expression, isolated from PBMC’s and measured by reverse transcription polymerase chain reaction, were elevated in peripheral blood monocytes of Alzheimer’s patients over healthy control patient samples. Peripheral blood mononuclear cells (PBMCs) from age matched healthy controls (HC) and Alzheimer’s (AD) subjects were separated using Ficoll Paque TM Plus (GE Healthcare) and the buffy coat (containing the leukocyte population) was harvested. Cells were washed, pelleted and stored at -80°C until later use. mRNA was isolated from the frozen cells and then converted into cDNA using oligo-dT, random hexamers, and Superscript RT II (Invitrogen, Grand Island, NY, USA). Reverse transcription-PCR was performed using TaqMan PCR master mix (Applied Biosystems, Foster City, CA, USA) and primers. Reactions were conducted on the ABI Prism 7000 Sequence Detection System (Applied Biosystems). Using an accessible biological sample and a simplified laboratory identification technique, CCR6 expression levels can be used as a biomarker of Alzheimer’s disease.

Patent Status:

US Provisional patent application filed 6/29/2010

PCT patent application filed 6/28/2011. Published Jan. 12, 2012 WO 2012/006056

US National Phase patent application s/n 13/806,394 filed Dec. 21, 2012

Relevant Publications:

Subramanian S et al, CCR6: A biomarker for Alzheimer’s-like disease in a triple transgenic mouse model. J Alzheimer’s Dis 2010 22:(2):619-629.

Inventor Profiles:

Dr. Halina Offner is a professor in the Department of Neurology at Oregon Health & Science University with a joint appointment in the Department of Anesthesiology and Peri-Operative Medicine. Her research interests include multiple sclerosis, experimental autoimmune encephalomyelitis, influence of sex hormones on autoimmunity, neuroimmunology, and stroke. Dr. Offner’s work is extensively published, with over 250 articles and book chapters in press.

Joseph F. Quinn, M.D. is an assistant professor, Department of Neurology and staff neurologist, Portland VAMC. .

Sandya Subramanian is a research associate, Department of Neurology.



For more information, contact:

Michele Gunness
Senior Technology Development Manager